Left Ventricular Dysfunction clinical trials at UCLA
2 in progress, 1 open to eligible people
Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
open to eligible people ages up to 17 years
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Los Angeles, California and other locations
BioVentrix Revivent TC™ System Clinical Study
Sorry, in progress, not accepting new patients
A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.
Los Angeles, California and other locations
Our lead scientists for Left Ventricular Dysfunction research studies include Nancy J. Halnon, MD.
Last updated: